The number of lives lost due to viral hepatitis infections is increasing and already accounts for 3,500 deaths daily, according to this report by the World Health Organization (WHO).
Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022-2030 guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis B and C and sexually transmitted infections by 2030.
This report provides accountability for the 3 Global Health Sector Strategies (2016-2021) on HIV, Viral Hepatitis and the STIs. The report assesses the impact, progress and gaps, and identifies actions to improve impact.
The device called “AJO-Neo” is developed by Professor Samir K. Pal &his group at S.N. Bose National Centre For Basic Sciences (SNBNCBS), Kolkata, an autonomous research Institute under the Department of Science and Technology (DST), Government of India.
The prices and the coverage of effective direct-acting antivirals (DAAs) to treat hepatitis C vary across countries. South Korea expanded DAAs coverage through national health insurance.
Cases of hepatitis-C are increasing in the district every year. Health Department data says the district has witnessed 6.5-fold increase in cases between 2014 and 2018.
The National Viral Hepatitis Control Programme, a new initiative under the National Health Mission, marks the beginning of the nation’s journey to control Viral Hepatitis and thereby reducing mortality and morbidity attributed to it. It is envisioned that this programme wilt reach large number of persons possible harboring the infection.
In line with the Government of India’s deep commitment towards elimination of viral hepatitis, the “National Action Plan – Viral Hepatitis” was launched by Union Minister of State, Health & Family Welfare. Viral hepatitis is recognized as an important public health problem across the world.
The revolution in hepatitis C virus (HCV) treatment through the development of direct-acting antivirals (DAAs) has generated international interest in the global elimination of the disease as a public health threat. In 2017, this led WHO to establish elimination targets for 2030.
